Selected markers of endothelial dysfunction in patients with subclinical and overt hyperthyroidism;Wybrane wskaźniki uszkodzenia śródbłonka wśród pacjentów z subkliniczna̧ i jawna̧ nadczynnościa̧ tarczycy

Endokrynologia Polska

Volumn 57, Issue 3, 2006, Pages 202-209

  Modzelewska, Anna ^a   Szelachowska, Małgorzata ^a   Zonenberg, Anna ^a   Abdelrazek, Saeid ^a   Nikołajuk, Agnieszka ^a   Górska, Maria ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Endothelial dysfunction; Overt and subclinical hyperthyroidism

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; INTERLEUKIN 6; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COMORBIDITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERTHYROIDISM; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REFERENCE VALUE; SECRETION; THYROID FUNCTION TEST; VASCULAR ENDOTHELIUM;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; COMORBIDITY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTHYROIDISM; INTERLEUKIN-6; MALE; MIDDLE AGED; REFERENCE VALUES; THYROID FUNCTION TESTS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 34249930936     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(supl. 4):S1-S14. (Pubitemid 23329995)
2. Abdu TA, Elhadd TA, Pfeifer M i wsp. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001;12:257-265. (Pubitemid 33714216)
3. Calles-Escadon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001;22:36-52. (Pubitemid 32187802)
4. Steinberg HO, Chaker H, Leaming R i wsp. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;11:2601-2610.
5. Burggraaf J, Lalezari S, Emeis JJ i wsp. Endothelial dysfunction in Patients with Hyperthyroidism Before and After Treatment with Propanolol and Thiamazol. Thyroid 2001;11:153-160. (Pubitemid 32221038)
6. Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormone. J Clin Invest 1972;51:2077-2084.
7. Spencer C. Serum TSH measurement: A 1990 status raport. Thyroid Today 1990;13:1-12.
8. Volzke H, Ludemann J, Robinson DM i wsp. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003;13:803-810. (Pubitemid 37070159)
9. Marcocci C, Bartalena L, Rocchi R i wsp. Long-term safety of orbital radiotherapy for Graves' ophathalmopathy. J Clin Endocrinol Metabol 2003;88:3561-3565.
10. Reinwein D, Benker G, Konig MP i wsp. The different types of hyperthyroidism in Europe. Results of a prospective survey of 924 patients. J Endocrinol Invest 1988;11:193-200.
11. Szybiński Z, Zarnecki A. Prevalence of goiter, iodine deficiency and iodine prophylaxis in Poland. The results of a nationwide study. Endokryn Pol 1993;44:373-388.
12. Klein I, Ojamaa K. Mechanizm of disease. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509. (Pubitemid 32164903)
13. Burmeister LA, Flores A. Subclinical Thyrotoxicosis and the Heart. Thyroid 2002;12:495-499. (Pubitemid 34721546)
14. Sawin CT, Geller A, Wolf PA. Low serum thyrotropin concentrations as a risk factor for atriall fibrillation in older patients. N Engl J Med 1994;331:1249-1252. (Pubitemid 24333188)
15. Auer J, Scheibner P, Mishce T i wsp. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142:838-842. (Pubitemid 33016203)
16. Wenisch C, Myskiw D, Gessel A i wsp. Circulating selectines, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab 1995;80:2122-2126.
17. Modelska-Ziolkiewicz A, Gembicki M, Sowinski Z. Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter. Pol Arch Med Wewn 2003;109:463-468.
18. De Bellis A, Bizzarro A, Gattoni A i wsp. Behavior of soluble intercellular molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and patients with toxic adenoma. J Clin Endocrinol Metab 1995;80:2118-2121.
19. Myśliwiec J, Kretowski A, Szelachowska M i wsp. Serum L-selectin and ICAM-1 in patients with Graves'ophthalmopathy during treatment with corticosteroids. Immunology Letters 2001;39:123-126. (Pubitemid 32905383)
20. Jurgielewicz DH, Rogowski F, Lebkowska U i wsp. E-selectin, L-selectin, ICAM-1 and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine I-131 therapy. Nucl Med Rev Cent East Eur 2002;5:39-42. (Pubitemid 34705109)
21. Bendtzen K, Buschard K, Diamant M i wsp. Possible role of IL-1, TNF-alpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Thyroid Group Lymphokine Res 1989;8:335-340. (Pubitemid 19215544)
22. Castell JV, Gomez-Lechon MJ, David M i wsp. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-239. (Pubitemid 19020112)
23. Akalin A, Colak A, Alatas O i wsp. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrin 2002;57:125-129. (Pubitemid 34785893)
24. Wahrenberg H, Wennlund A, Hoffstedt J. Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumor necrosis factor alpha, in Graves' hyperthyroidism. Eur J Endocrin 2002;146:607-611. (Pubitemid 34552492)
25. Sentruk T, Kozaci LD, Kok F i wsp. Proinflammatory cytokines levels in hyperthyroidism. Clin Invest Med 2003;26:58-63.
26. Jyonouchi SC, Valyasevi RW, Harteneck DA i wsp. Interleukin-6 stimulates thyrotropin receptor expressin in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid 2001;11:929-934. (Pubitemid 33020179)
27. Botella-Carretero JI, Prados A, Manzano L i wsp. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied In patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. Eur J Endocrin 2005;153:223-230. (Pubitemid 41167480)
28. Gietka-Czernel M, Jastrzȩbska H. Rozpoznawanie i leczenie chorób tarczycy. Biblioteka Lekarza Praktyka. OINpharma, Warszawa 2002.
29. Grzesiuk W. Subkliniczna nadczynność tarczycy. Pol Merkuriusz Lek 2001;56:107-109.